Rheinmetall could be worth 17 billion euros over medium term, CEO says

Media tour at Rheinmetall plant in UnterluessThe logo of Rheinmetall is seen at a production line of German company Rheinmetall, which produces weapons and ammunition for tanks and artillery, during a media tour at the company’s plant in Unterluess, Germany, June 6, 2023. REUTERS/Fabian Bimmer

BERLIN, June 10 (Reuters) – The CEO of Germany's largest defence contractor Rheinmetall (RHMG.DE) said he expected a further boost to the company's stock market value due to the Ukraine war and increased defence spending in Europe.

"Our operating income in 2025 should be about 1.5 billion euros ($1.6 billion), maybe even 1.7 billion euros. For a fair valuation, multiply that with a factor of 11 or 12. That gives you an order of magnitude," CEO Armin Papperger told German newspaper publisher RND in an interview published on Satursday.

"A valuation of 17 billion euros is realistic for Rheinmetall over the medium term," he added.

Rheinmetall's current stock valuation is about 10.5 billion euros, on 2022 operating income of 754 million euros.

The stock market value of the company, a maker of tanks, ammunition and other war equipment, has tripled since December 2021 and it joined Germany's blue-chip DAX (.GDAXI) index earlier this year.

($1 = 0.9305 euros)

  • WorldcategoryUkraine's army reports new gains against Russian forces near BakhmutJune 10, 2023
  • WorldcategoryZelenskiy: Counteroffensive actions taking place in Ukraine1:20 AM UTC
  • article with galleryWorldcategoryChild plane crash survivors in "acceptable" state of healthJune 10, 2023
  • article with galleryAerospace & DefensecategoryNo injuries after planes collide on ground at Tokyo's Haneda airport, NHK reportsJune 10, 2023


Related posts

Airlines forced to ration jet fuel in New Zealand, but limited impact seen

Cynthia Danforth

Analysis: SVB collapse unleashes Treasury volatility, whiplashing investors

Cynthia Danforth

China’s Tencent Music beats revenue estimates on higher subscriptions

Cynthia Danforth

Leave a Comment